Phase II Trial of Hypofractionated Image-Guided Intensity-Modulated Radiotherapy for Localized Prostate Adenocarcinoma
- 5 July 2007
- journal article
- Published by Elsevier in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
- Vol. 69 (4) , 1084-1089
Abstract
No abstract availableKeywords
This publication has 18 references indexed in Scilit:
- Dose-Response in Radiotherapy for Localized Prostate Cancer: Results of the Dutch Multicenter Randomized Phase III Trial Comparing 68 Gy of Radiotherapy With 78 GyJournal of Clinical Oncology, 2006
- Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Long-term outcomesInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2005
- Comparison of Conventional-Dose vs High-Dose Conformal Radiation Therapy in Clinically Localized Adenocarcinoma of the ProstateJAMA, 2005
- A phase II study of localized prostate cancer treated to 75.6Gy with 3D conformal radiotherapyRadiotherapy and Oncology, 2005
- The radiobiology of prostate cancer including new aspects of fractionated radiotherapyActa Oncologica, 2005
- Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trialInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2002
- Preliminary observations on biochemical relapse-free survival rates after short-course intensity-modulated radiotherapy (70 Gy at 2.5 Gy/fraction) for localized prostate cancerInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2002
- External beam radiotherapy dose response characteristics of 1127 men with prostate cancer treated in the PSA eraInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2000
- Fractionation and protraction for radiotherapy of prostate carcinomaInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1999
- Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trialThe Lancet, 1999